Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types.

adaptive immunity cutaneous melanoma driver mutations liver metastases metastatic uveal melanoma uveal melanoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 Jun 2019
Historique:
received: 30 05 2019
revised: 16 06 2019
accepted: 17 06 2019
entrez: 29 6 2019
pubmed: 30 6 2019
medline: 30 6 2019
Statut: epublish

Résumé

Here, we critically evaluated the knowledge on cutaneous melanoma (CM) and uveal melanoma (UM). Both cancer types derive from melanocytes that share the same embryonic origin and display the same cellular function. Despite their common origin, both CM and UM display extreme differences in their genetic alterations and biological behavior. We discuss the differences in genetic alterations, metastatic routes, tumor biology, and tumor-host interactions in the context of their clinical responses to targeted- and immunotherapy.

Identifiants

pubmed: 31248118
pii: cancers11060845
doi: 10.3390/cancers11060845
pmc: PMC6627906
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Ann Oncol. 2013 Nov;24(11):2911-5
pubmed: 24067719
Acta Ophthalmol. 2018 Feb;96(1):31-38
pubmed: 28444874
Oncotarget. 2017 May 9;8(19):31079-31091
pubmed: 28415693
Melanoma Res. 2017 Jun;27(3):200-210
pubmed: 28272106
Clin Cancer Res. 2013 Nov 15;19(22):6329-30
pubmed: 24166902
Cancer Res. 2002 Oct 15;62(20):5930-8
pubmed: 12384559
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
pubmed: 18980976
Mol Cancer Res. 2018 Dec;16(12):1902-1911
pubmed: 30093564
Exp Dermatol. 2016 Nov;25(11):831-838
pubmed: 27792246
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Lab Invest. 2006 Mar;86(3):231-45
pubmed: 16446705
Dermatol Pract Concept. 2019 Jan 31;9(1):54-62
pubmed: 30775150
BMC Cancer. 2014 Jan 10;14:13
pubmed: 24410877
N Engl J Med. 2010 Dec 2;363(23):2191-9
pubmed: 21083380
Clin Cancer Res. 2012 Jan 15;18(2):408-16
pubmed: 22038994
Cancer. 2016 Nov 15;122(21):3344-3353
pubmed: 27533448
PLoS One. 2016 Oct 20;11(10):e0164292
pubmed: 27764126
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4372-5
pubmed: 16303922
Melanoma Res. 2016 Jun;26(3):300-3
pubmed: 26848796
Br J Cancer. 2017 Feb 14;116(4):432-440
pubmed: 28103611
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
J Exp Med. 2003 Nov 3;198(9):1337-47
pubmed: 14581607
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Immunol Immunother. 2015 Oct;64(10):1271-86
pubmed: 26122357
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Invest New Drugs. 2020 Feb;38(1):20-28
pubmed: 30887251
Cancer. 2010 May 1;116(9):2224-33
pubmed: 20209608
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43
pubmed: 18235009
Cell Mol Immunol. 2006 Aug;3(4):285-90
pubmed: 16978537
Nat Rev Drug Discov. 2003 Oct;2(10):803-11
pubmed: 14526383
J Clin Oncol. 2004 Jul 15;22(14):2891-900
pubmed: 15254058
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Arch Ophthalmol. 2006 Jan;124(1):54-60
pubmed: 16401785
Acta Ophthalmol. 2012 Dec;90(8):e638-44
pubmed: 23164171
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Adv Anat Pathol. 2019 Jan;26(1):69-74
pubmed: 30339548
Eur J Cancer. 2017 Sep;82:56-65
pubmed: 28648699
Cancer Immunol Immunother. 2017 Jul;66(7):903-912
pubmed: 28391358
Eur J Cancer. 2006 May;42(8):1181-7
pubmed: 16644201
Clin Cancer Res. 2008 Feb 15;14(4):951-6
pubmed: 18281525
Oncotarget. 2017 Dec 15;9(5):6174-6187
pubmed: 29464063
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Cancer Immunol Res. 2018 Apr;6(4):481-493
pubmed: 29467127
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
Melanoma Res. 2017 Dec;27(6):558-564
pubmed: 28885396
Oncotarget. 2016 Jul 22;8(35):58021-58036
pubmed: 28938534
Oncoimmunology. 2017 May 8;6(6):e1321187
pubmed: 28680759
Oncologist. 2015 Nov;20(11):1312-9
pubmed: 26424760
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):490-3
pubmed: 23197685
Clin Cancer Res. 2013 Jun 15;19(12):3143-52
pubmed: 23633454
Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi
pubmed: 22682634
Oncogene. 2016 May 19;35(20):2675-80
pubmed: 26119932
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
Curr Signal Transduct Ther. 2013 Dec;8(3):193-202
pubmed: 25045345
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8
pubmed: 11773005
Clin Cancer Res. 2019 Apr 1;25(7):2206-2218
pubmed: 30563937
Anticancer Res. 2018 Jul;38(7):3817-3824
pubmed: 29970501
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Arch Dermatol Res. 2012 Apr;304(3):185-93
pubmed: 22350183
J Photochem Photobiol B. 1992 Feb 28;12(3):215-58
pubmed: 1635010
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Anticancer Res. 2014 Sep;34(9):5217-20
pubmed: 25202118
Mol Cancer. 2015 May 14;14:103
pubmed: 25971889
Cancers (Basel). 2016 Jan 15;8(1):
pubmed: 26784231
Invest Ophthalmol Vis Sci. 2013 Nov 08;54(12):7354-61
pubmed: 24052640
Nat Rev Cancer. 2004 Jul;4(7):540-50
pubmed: 15229479
Oncotarget. 2015 Nov 10;6(35):37824-35
pubmed: 26462151
Pathol Oncol Res. 2010 Sep;16(3):303-9
pubmed: 20306313
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Cancer Med. 2017 Jul;6(7):1581-1586
pubmed: 28639409
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Cancer Res. 2016 Jan 15;76(2):390-402
pubmed: 26577700
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
J Clin Oncol. 2011 Jul 20;29(21):2904-9
pubmed: 21690468
J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43
pubmed: 11698568
Oncotarget. 2017 May 9;8(19):32258-32269
pubmed: 28416755
Ann Oncol. 2017 Jun 01;28(6):1380-1387
pubmed: 28327988
Cancer Immunol Res. 2017 Feb;5(2):170-179
pubmed: 28073773
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
PLoS One. 2015 Mar 11;10(3):e0118564
pubmed: 25761109
PLoS One. 2017 Jun 8;12(6):e0178189
pubmed: 28594900
J Cell Biochem. 2003 Jun 1;89(3):462-73
pubmed: 12761880
Photochem Photobiol. 2008 May-Jun;84(3):539-49
pubmed: 18435612
Cancer Discov. 2018 Nov;8(11):1366-1375
pubmed: 30209080
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4
pubmed: 18719078
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Adv Pharmacol. 2012;65:27-43
pubmed: 22959022
Ocul Oncol Pathol. 2015 Apr;1(3):170-81
pubmed: 27171126
Pigment Cell Melanoma Res. 2014 Mar;27(2):297-308
pubmed: 24354797
BMC Cancer. 2017 Aug 10;17(1):536
pubmed: 28797232
Acta Oncol. 2020 Jul;59(7):833-844
pubmed: 32285732
Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2603-6
pubmed: 8325762
Am J Clin Dermatol. 2019 Jun;20(3):315-323
pubmed: 30707374
Oncotarget. 2015 Nov 24;6(37):39877-90
pubmed: 26497996
Acta Oncol. 2017 Jan;56(1):101-103
pubmed: 27911126
Science. 2010 Dec 3;330(6009):1410-3
pubmed: 21051595
Cancer. 2013 Oct 15;119(20):3687-95
pubmed: 23913718
Br J Cancer. 2013 Jul 23;109(2):493-6
pubmed: 23778528
Cancer Immunol Res. 2015 Dec;3(12):1375-85
pubmed: 26297712
JAMA. 2011 Jun 8;305(22):2327-34
pubmed: 21642685
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Sci Rep. 2016 Mar 04;6:22622
pubmed: 26940009
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Cancer Immunol Immunother. 2008 Jan;57(1):97-106
pubmed: 17602225
J Clin Oncol. 2013 Sep 10;31(26):3182-90
pubmed: 23775962
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
J Surg Oncol. 2004 Jul 1;86(4):172-8
pubmed: 15221923
Lancet Oncol. 2017 Jun;18(6):792-802
pubmed: 28395880
Oncol Rep. 2007 Nov;18(5):1115-22
pubmed: 17914561
Br J Cancer. 2013 Apr 30;108(8):1634-40
pubmed: 23538388
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Invest Ophthalmol Vis Sci. 2012 Aug 09;53(9):5370-8
pubmed: 22743317
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Clin Cancer Res. 2013 Oct 1;19(19):5300-9
pubmed: 24089443
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Acta Oncol. 2013 Nov;52(8):1786-8
pubmed: 23607756
Br J Cancer. 2009 Sep 1;101(5):813-5
pubmed: 19654573
J Biol Chem. 2002 Dec 20;277(51):49481-7
pubmed: 12388552

Auteurs

Monique K van der Kooij (MK)

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. m.k.van_der_kooij@lumc.nl.

Frank M Speetjens (FM)

Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. f.m.speetjens@lumc.nl.

Sjoerd H van der Burg (SH)

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. s.h.van_der_burg@lumc.nl.

Ellen Kapiteijn (E)

Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. h.w.kapiteijn@lumc.nl.

Classifications MeSH